Chiral Pyrrolo[2,3-<i>d</i>]pyrimidine and Pyrimido[4,5-<i>b</i>]indole Derivatives: Structure−Activity Relationships of Potent, Highly Stereoselective A<sub>1</sub>-Adenosine Receptor Antagonists<sup>,</sup>
作者:Christa E. Müller、Uli Geis、Bettina Grahner、Wolfgang Lanzner、Kurt Eger
DOI:10.1021/jm960011w
日期:1996.1.1
A1AR antagonists compared to pyrrolo[2,3-d]pyrimidines. Compound 34a (APEPI) is one of the most potent and most selective nonxanthine A1AR antagonists known to date (Ki = 2.8 nM, > 2000-fold A1-selective). A new class of very potent A1AR antagonists has been identified, namely, 2-phenyl-7-deazaadenines bearing a substituent at the exocyclic amino group (N4-substituted pyrrolo[2,3-d]pyrimidines). (R)-N-
合成了33种新颖的,主要是手性的吡咯并[2,3-d]嘧啶和嘧啶并[4,5-b]吲哚衍生物,并在高亲和力腺苷受体(AR)亚型A1和A的放射性配体结合测定中进行了研究。 A2a。可以设想这些化合物为在7位上缺少氮的腺嘌呤和次黄嘌呤类似物(7-deazaadenines和7-deazahypoxanthines)。7-脱氮杂腺嘌呤在AR上的亲和力比7-脱氮杂泛黄嘌呤要强得多,A1AR亲和力在低纳摩尔范围内,对大鼠脑A1AR的选择性相对于A2aAR异常高(几千倍),并且立体选择性高(高达96倍)。与吡咯并[2,3-d]嘧啶相比,嘧啶并[4,5-b]吲哚是更有效的A1AR拮抗剂。化合物34a(APEPI)是迄今为止已知的最有效和最具选择性的非黄嘌呤A1AR拮抗剂之一(Ki = 2。8 nM,> 2000倍A1选择性)。已经鉴定出一类新的非常有效的A1AR拮抗剂,即在环外氨基上带有取代基的2-苯基-7-脱氮杂腺嘌呤(N4-取代的吡咯并[2